Gentian Diagnostics (GENT.OL) Stock Analysis & AI Equity Report
Gentian Diagnostics (GENT.OL) overview
Gentian Diagnostics (GENT.OL) stock analysis and AI equity research. For the latest completed financial year, 2024, Gentian Diagnostics reported revenue of NOK 152m and operating profit of NOK 15.7m; the year-end share price was 39.20 NOK and market capitalisation was NOK 605m. Gentian Diagnostics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Gentian Diagnostics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-01-29. Data will be refreshed during report generation.
About Gentian Diagnostics
Gentian Diagnostics ASA develops and manufactures in vitro diagnostic reagents and open-channel turbidimetric assays for clinical chemistry analyzers. Its portfolio covers kidney disease, cardiac disease, inflammation, infection and veterinary medicine. The company sells through OEM partners, distributors and direct channels in global human and animal diagnostics markets, with manufacturing and offices in Norway and abroad.
Generate the Gentian Diagnostics report
Gentian Diagnostics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Gentian Diagnostics and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.